Project Grant R43CA257552
Award Date
5/1/21
Completion Date
4/30/22
Dollars Obligated
$1.2M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Tampa, FL 33612, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) totaling $367,472 will fund the development of a novel ablative therapy for the treatment of cervical intraepithelial neoplasia (CIN), a precancerous cervical condition caused by the human papillomavirus (HPV). The award recipient, Gynion LLC, will focus the Phase I study on developing a cervical applicator and refining a gel formulation containing trichloroacetic acid (TCA) as the...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $1,172,978 to Ananya Health Inc. to develop a portable, battery-powered, closed-loop cryotherapy system for the treatment of cervical precancerous lesions in low- and middle-income countries (LMICs). The system, called CRCL, is designed to provide an affordable and accessible cryotherapy solution that does not require consumable cryogen gas, a key barrier to widespread...
This $600,534 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development of Link Biosystems Inc.'s bioreactor technologies to efficiently generate large quantities of "immunocompetent tumoroid tissues" from patient tumor samples. These tumoroid tissues will enable enhanced preclinical screening of cancer therapeutics, including immunotherapies, biologics, and drug combinations, to identify optimal treatment regimens...
This $798,512 Project Grant was awarded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) to Luminary Therapeutics, Inc., a small disadvantaged business located in Minnesota. The grant will fund the development of an allogeneic gamma/delta T-cell-based chimeric antigen receptor (CAR) therapy that targets two antigens, mesothelin and chondroitin sulfate proteoglycan-4, expressed in epithelial ovarian carcinoma. The therapy incorporates innovative...
The National Cancer Institute (NCI) awarded a $619,294 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to the University of California, San Diego (UCSD) to develop and test slow-release CPMV-polymer blend formulations for intratumoral immunotherapy delivery. The project aims to address key challenges with intratumoral immunotherapy, including large tumor volumes, high fluid pressure, and frequent dosing requirements, by developing injectable CPMV-polymer implants and...
The National Cancer Institute (NCI) awarded Chemedimmune, Inc. a $320,597 Project Grant (CFDA 93.395 - Cancer Treatment Research) to develop IFNA2-LNP01, a lipid nanoparticle-encapsulated IFN2-encoding mini-plasmid DNA, for the treatment of lung metastases. The project aims to: 1) determine the efficacy of IFNA2-LNP01 in suppressing tumor lung metastases in vivo, and 2) evaluate the biodistribution and toxicology of IFNA2-LNP01 in vivo. This work is expected to generate the necessary data to...
The National Cancer Institute (NCI) awarded Privo Technologies, Inc. a $2,084,026 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to support a Phase 3 clinical trial for their nanotechnology-based topical treatment, PRV111, for carcinoma in situ of the oral cavity (early-stage oral cancer). The grant, running from June 2024 through May 2027, aims to demonstrate the efficacy of PRV111 as a chemoablative alternative to invasive surgical resection, which can lead to...
The National Cancer Institute (NCI) awarded Celdara Medical, LLC a $1,024,967 Project Grant (CFDA 93.395 - Cancer Treatment Research) to develop CM-HZ01, a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. The project aims to advance CM-HZ01 to investigational new drug (IND) status as a best-in-class immunotherapy for patients with limited effective treatment options for this deadly form of skin cancer. The funding supports the research and development of CM-HZ01, an engineered...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides funding of $361,635 to Immunebro Therapeutics Inc. to develop enhanced "Engager T Cells" - a novel off-the-shelf T cell therapy platform for cancer treatment. The key products or services to be delivered under this award are: Development of enhanced CD19-targeting Engager T cells with improved efficacy compared to current second-generation CD19 CAR T cells, through...
This Project Grant award of $427,095 from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program will fund the development of a novel microfluidic droplet-based platform (MDP) technology at Northeastern University. The goal is to generate and analyze a 3D biomimetic multicellular immunogenic tumor model that can: Establish multiple levels of hypoxia within the same tumor-chip for parallel processing; Investigate spatiotemporal interaction...